Delving into the Latest Updates on Cariprazine hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

cariprazine, Cariprazine hydrochloride (JAN/USAN), SYMVENU

+ [11]

Target

5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor

Action

agonists, antagonists, partial agonists

Mechanism

5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor partial agonists(Dopamine D2 receptor partial agonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesCardiovascular Diseases+ [1]

Active Indication

Depressive Disorder, MajorBipolar and Related DisordersBipolar Disorder+ [7]

Inactive Indication

Bipolar II disorderChronic schizophreniaGeneralized anxiety disorder+ [2]

Originator Organization

Chemical Works of Gedeon Richter Plc

Active Organization

Qilu Pharmaceutical Co., Ltd.Gedeon Richter (UK) Ltd.

AbbVie, Inc.

+ [4]

Inactive Organization

Forest Laboratories LLC

Tanabe Pharma Corp.Gedeon Richter Pharma GmbH

+ [1]

License Organization

Gedeon Richter (UK) Ltd.

Chemical Works of Gedeon Richter Plc

Hikma Pharmaceuticals Plc

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (17 Sep 2015),

Bipolar I disorderSchizophrenia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H33Cl3N4O

InChIKeyGPPJWWMREQHLQT-BHQIMSFRSA-N

CAS Registry1083076-69-0

Bipolar disorder is a common condition that can cause significant disability and risk for suicide. Second generation antipsychotic medications can be used to treat depression in bipolar disorder, yet we do not know how they work. Here, we will use a recently approved medication, cariprazine (Vraylar), to treat participants with bipolar depression. They will have brain imaging with PET scans before and during treatment to understand how the medication may be working. Particularly, we will look at the role of the D3 dopamine receptor.

Start Date06 Jan 2026

Sponsor / Collaborator

The New York State Psychiatric Institute

NCT07266545

/ Not yet recruitingPhase 4IIT

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

The purpose of this research is to understand how changes in RNA editing relate to treatment response in unipolar and bipolar depression.

Start Date31 Dec 2025

Sponsor / Collaborator

Mayo Clinic

CTR20253439

/ RecruitingPhase 3

评价盐酸卡利拉嗪胶囊治疗精神分裂症急性发作期患者的有效性和安全性的多中心、随机、双盲双模拟、阳性药物平行对照Ⅲ期临床研究

[Translation] A multicenter, randomized, double-blind, double-dummy, positive drug parallel controlled phase III clinical study to evaluate the efficacy and safety of cariprazine hydrochloride capsules in the treatment of patients with acute exacerbation of schizophrenia

以阿立哌唑片为对照药，通过多中心、随机、双盲双模拟、平行对照设计的临床试验，评价盐酸卡利拉嗪胶囊治疗精神分裂症急性发作期患者的有效性和安全性

[Translation]

A multicenter, randomized, double-blind, double-dummy, parallel controlled clinical trial was conducted to evaluate the efficacy and safety of cariprazine hydrochloride capsules in the treatment of patients with acute exacerbation of schizophrenia, using aripiprazole tablets as the control drug.

Start Date22 Oct 2025

Sponsor / Collaborator

Jiangsu Nhwa Pharmaceutical Co., Ltd.

100 Clinical Results associated with Cariprazine hydrochloride

Login to view more data

100 Translational Medicine associated with Cariprazine hydrochloride

Login to view more data

100 Patents (Medical) associated with Cariprazine hydrochloride

Login to view more data

552

Literatures (Medical) associated with Cariprazine hydrochloride

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States

Article

Author: Ta, Jamie ; Martínez, Cristina ; Laliberté, François ; Parikh, Mousam ; Lejeune, Dominique ; Zanardo, Enrico ; Nabulsi, Nadia ; Masand, Prakash S.

AIM:

To compare all-cause and mental health (MH)-related short-term and long-term disability leaves and associated costs among patients in the United States with bipolar disorder (BP), major depressive disorder (MDD), or schizophrenia spectrum disorders (SCZ) before versus after cariprazine initiation.

METHODS:

Merative MarketScan Commercial and Health and Productivity Management (HPM) databases (January 2016 to December 2021) were utilized to identify adults diagnosed with BP, MDD, or SCZ with ≥2 pharmacy cariprazine claims (first claim = index), ≥3 months of cariprazine use (adjunctively for MDD), and continuous commercial insurance coverage and HPM eligibility during baseline (12 months pre-index) and ≥3 months post-index. Observation continued until cariprazine discontinuation, insurance or HPM eligibility end, 1 year post-index, or HPM data availability end. All-cause and MH-related disability claims, days, and costs were evaluated. Baseline versus post-index rates of disability claims (events) and days were compared using rate ratios (RR); costs were compared using mean cost differences. Comparisons were calculated from generalized estimating equation models. Analyses were replicated separately across indications.

RESULTS:

There were 489 patients overall (BP = 238, MDD = 233, SCZ = 18; mean age = 43.3 years; 60.7% female; mean follow-up = 7.6 months). All-cause rates of disability events and days following cariprazine initiation were 29% (RR = 0.71 [95% CI = 0.57, 0.86]) and 28% (0.72 [0.53, 0.94]) lower than baseline, respectively (both p < .05). MH-related rates of disability events and days were 40% (0.60 [0.43, 0.80]) and 43% (0.57 [0.34, 0.84]) lower, respectively (both p < .01). All-cause disability costs were $2,917 lower and MH-related disability costs were $2,482 lower than baseline (40% and 51% decrease, respectively; both p < .01). Results were similar for indication-specific analyses.

LIMITATIONS:

Limited generalizability to patients who are unemployed, uninsured, or have public insurance.

CONCLUSIONS:

Rates of disability events, days, and mean costs were significantly lower after versus before cariprazine initiation. These results can help contextualize cariprazine's role in managing disability for these patients.

01 Nov 2025·JOURNAL OF AFFECTIVE DISORDERS

Adverse events associated with four atypical antipsychotics used as augmentation treatment for major depressive disorder: A pharmacovigilance study based on the FAERS database

Article

Author: Qi, Fangqing ; Tian, Leiyu ; Zhang, Xiangyang ; Qu, Miao ; Zhang, Yingjie ; Zhao, Simin ; Li, Fei ; Diao, Huaqiong

BACKGROUND:

There is insufficient understanding of the long-term studies on adverse events (ADEs) in major depressive disorder (MDD) treated with atypical antipsychotics (AAPs), risks in patients with different psychiatric disorders, and differences between male and female patients.

METHODS:

This study retrieved ADE reports for aripiprazole, quetiapine XR, brexpiprazole, and cariprazine from the FDA Adverse Event Reporting System (FAERS) for the time periods of FDA approval for MDD in the first quarter (Q1) of 2007, the Q1 of 2009, the Q1 of 2015, and the Q1 of 2022 respectively to the Q1 of 2024. Four algorithms (ROR, PRR, BCPNN, and MGPS) assessed ADE signals. We compared positive signal rates between MDD and non-MDD, and assessed sex differences in drug-related risks by ROR.

RESULTS:

Patients with MDD had significantly higher rates of impulse control disorders (ICDs), obsessive-compulsive disorder (OCD), weight gain, extrapyramidal symptoms, and metabolic disorders compared to non-MDD (P < 0.05). Restless legs syndrome was associated with aripiprazole (P < 0.01), brexpiprazole (P < 0.01), and quetiapine XR. Serotonin syndrome, eosinophilic myocarditis, and angle-closure glaucoma were new signals of aripiprazole in patients with MDD (P < 0.05). Female patients were more likely to gain weight (P < 0.05) with using aripiprazole, quetiapine XR, and brexpiprazole, whereas male patients with aripiprazole (P < 0.01) or brexpiprazole (P < 0.05) reported higher rates of ICDs and OCD.

CONCLUSION:

It is suggesting a potential increased risk of various ADEs in patients with MDD when taking AAPs. The causal relationship and the exact mechanism between drugs and ADEs remains unclear, requiring further research.

15 Oct 2025·Cureus Journal of Medical Science

An “Awakener” Patient Suffering From Treatment-Resistant Depression Following Adjunctive Cariprazine

Author: Bonotis, Konstantinos

[This corrects the article DOI: 10.7759/cureus.53246.].

92

News (Medical) associated with Cariprazine hydrochloride

01 Dec 2025

·www.globenewswire.com

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Management to Participate in 8th Annual Evercore Annual Healthcare ConferenceNESS ZIONA, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 8th Annual Evercore Annual Healthcare Conference, to take place December 2-4, 2025, in Miami, Florida. Mapi is actively seeking additional partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the Annual Evercore Annual Healthcare Conference to discuss potential joint development collaborations. Interested parties should contact Mapi directly or their representative at Evercore to arrange a meeting. Mapi utilizes extended-release Depot technologies with strong IP to develop Lifecycle Management products for innovative and existing commercially successful pharmaceuticals across multiple therapeutic areas. The Company currently has one product which is fully under a commercialization agreement, GA Depot for Relapsing Forms of Multiple Sclerosis (RMS) and other products for diabetes and schizophrenia which are funded through Phase II results. The development pipeline also includes an injectable version of cariprazine, developed using Mapi’s Depot technology, which has demonstrated a long-acting release profile, for one monthly injection. It is designed to address an unmet need in the treatment of schizophrenia, bipolar I and major depression disorders. Mapi recently began enrolling patients in a Phase I/II study. Mapi is fully integrated in the development of Depot pharmaceuticals and offers partners multiple distinct technologies. The Company has an extensive R&D team with dedicated Depot labs, experienced clinical team, as well as a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply. Mapi has the capabilities to efficiently develop Depot products by integrating R&D, clinical studies, registration and manufacturing with a successful track record of improving time to market. Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma, said, “We have a number of compelling partnering opportunities in our current pipeline, including Deutetrabenazine (AUSTEDO® XR) Depot for the treatment of Huntington's disease and tardive dyskinesia, and Anastrazole (Arimidex®) Depot as an adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer as well as other candidates. We can also apply our technologies to co-develop Depot drugs with companies that are interested in developing long-acting injectable lifecycle management versions of their molecules." About Mapi PharmaMapi Pharma (Mapi) is a clinical stage pharmaceutical company, engaged in development of high barrier-to-entry and high added-value life cycle management ("LCM") products and AB Rated Depot injectable products that target large markets that include complex active pharmaceutical ingredients ("APIs") and formulations. Mapi’s lead product is GA Depot which is partnered with Viatris (NASDAQ: VTRS) in an agreement under which Viatris was granted an exclusive license to commercialize the GA Depot injection product for Relapsing Forms of Multiple Sclerosis (RMS). Following successful Phase 3 results GA Depot is currently under FDA review. The Company is also marketing its own generic versions of Fingolimod (Gilenya®) and Apremilast (Otezla®) in specific geographic markets. Mapi's portfolio also includes a leading development of Depot drugs for Schizophrenia, GLP-1 for diabetes, weight loss, with innovative intellectual property. Mapi is built on strong chemical and pharmaceutical R&D and clinical development capabilities and a deep understanding of the global market and of regulatory needs. Mapi is a global company with an API production and aseptic Depot manufacturing and a Fill & Finish for injectable Finished Dosage Forms facilities. Mapi has strong IP positions, filing numerous patent applications for APIs and formulations. For more information, please visit www.mapi-pharma.com Contacts:Alex MogleVice President, Corporate DevelopmentMapi Pharma+972 52 6080297alex@mapi-pharma.com Brian RitchieManaging DirectorLifeSci Advisors, LLCbritchie@lifesciadvisors.com

License out/inPhase 2Phase 3

26 Nov 2025

·pharma.economictimes.indiatimes.com

US Medicare price cuts manageable for most drugmakers, analysts say

London: U.S. Medicare price cuts of up to 85% will have a lesser impact on drugmakers than initially feared, with most of the hit already reflected in forecasts, Wall Street analysts said. Shares of Danish drugmaker Novo Nordisk and Teva Pharmaceuticals rose 5% and 3% respectively after the U.S. government published negotiated prices late on Tuesday. Novo's top-selling drug semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, as well as Teva's Austedo for Hungtington disease were among the closely watched drugs on the list of prices, which will take effect in 2027. The announcement and recent White House deals offer clarity on pricing for popular GLP-1 drugs such as Wegovy and Eli Lilly's Zepbound, which have drawn scrutiny over their costs. The negotiated price for Novo's semaglutide is "the final cloud to clear on the drawn-out, but positively resolved GLP-1 pricing debate ," said Bernstein analyst Christian Moore. The price cuts through the U.S. Medicare health plan come as President Donald Trump's administration pushes the drug industry to advocate for other wealthy nations, particularly in Europe, to pay more for prescription medicines. Goldman Sachs said a key question for the first half of 2026 will be whether lower Medicare prices boost Wegovy volumes. William Blair analysts noted the $274 monthly price for Novo's semaglutide broadly aligns with recent government deals, but said uncertainty remains over insurance coverage expansion. FACTORED INTO NOVO, ASTRAZENECA AND GSK FORECASTS Bernstein analysts said that five of the 15 targeted medicines will become generic by 2027, limiting their exposure to price cuts. The lower prices could even keep patients on the branded therapies longer, boosting volumes, they said. Analysts agreed that the reductions had been factored into estimates for Novo, AstraZeneca and GSK. Earlier this month, Novo said it expected a low single-digit impact to global sales if the price cuts were implemented this year. Analysts said that would imply roughly a 6 billion Danish crown ($931 million) sales hit. AstraZeneca and GSK shares were flat on Wednesday. GSK said when reporting third-quarter results that any impact from negotiated prices was fully factored into its outlook. Shore Capital analyst Sean Conroy said the cuts would hit earnings by "low- to mid-hundreds" of millions of pounds or dollars. Bernstein estimated the impact on Abbie in the range of $100 million to $250 million to sales of its mood disorder drug Vraylar and irritable bowel syndrome medicine Linzess as well as for Amgen's psoriasis drug Otezla. ($1 = 6.4404 Danish crowns) (Reporting by Bhanvi Satija and Maggie Fick in London, Stine Jacobsen in Copenhagen, Mariam Sunny and Mrinalika Roy in Bengaluru; Editing by Jane Merriman, Jan Harvey and Alexander Smith)

26 Nov 2025

·www.biopharmadive.com

CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs

Medicare will pay billions of dollars less in 2027 for 15 drugs, including major medicines for cancer, asthma and metabolic conditions, after completing the second annual round of price negotiations required under the Inflation Reduction Act.The Centers for Medicare and Medicaid Services on Tuesday announced the final prices, which, if they had been in place in 2024, would have reduced aggregate spending by 44%, or $12 billion. Beneficiaries out-of-pocket spending would have been reduced $685 million, the CMS said.The announcement concludes three rounds of negotiations between the agency and drugmakers, who made offers and counteroffers with a review of evidence supporting their respective proposals. CMS said the prices of seven were reached based on a revised counteroffer from the respective drugmakers. In seven other cases, the company accepted a written final offer from CMS.The price for semaglutide, the active ingredient in Novo Nordisks blockbuster obesity drug Wegovy and diabetes shot Ozempic, was preannounced in an Oval Office press conference with President Donald Trump. The administration is seeking to equalize prices between the U.S. and other industrialized nations.The drugs included on Medicare's latest round of price negotiations.DrugManufacturerNegotiated Price (30 day supply)List Price 20242024 Gross Covered CostEnrollees Who Used Drug in 2024SemaglutideNovo Nordisk$274$959$15.2 billion2.3 millionTrelegy ElliptaGSK$175$654$5.3 billion1.3 millionXtandiAstellas/Pfizer$7,004$13,480$3.4 billion35,000PomalystBristol Myers Squibb$8,650$21,744$2.2 billion14,000OfevBoehringer Ingelheim$6,350$12,622$2.1 billion24,000IbrancePfizer$7,871$15,741$2 billion16,000LinzessAbbVie$136$539$2 billion632,000CalquenceAstraZeneca$8,600$14,228$1.7 billion15,000AustedoTeva$4,093$6,623$1.7 billion27,000Breo ElliptaGSK$67$397$1.4 billion626,000XifaxanSalix$1,000$2,696$1.2 billion105,000VraylarAbbVie$770$1,376$1.1 billion118,000TradjentaBoehringer Ingelheim$78$488$1.1 billion274,000JanumetMerck & Co.$80$526$1.1 billion239,000OtezlaAmgen$1,650$4,722$1 billion31,000SOURCE: Centers for Medicare and Medicaid ServicesThe latest round also includes the diabetes drugs Tradjenta and Janumet; cancer medicines Xtandi, Pomalyst, Ibrance and Calquence; respiratory therapies Trelegy, Ofev, and Breo; and the gastrointestinal treatments Linzess and Xifaxan. Also on the list are Austedo, for irregular body movements; Vraylar, for depression; and Otezla, for psoriasis.The Inflation Reduction Act for the first time allowed for price negotiations under Medicare, which began covering pharmacist-dispensed drugs in 2006 under whats known as Part D. Prices for 10 drugs set under the first round of negotiations conducted in 2024 will go into effect in 2026, followed by these 15 in 2027.To be eligible for price negotiations, the drugs must be single-source, typically meaning branded products not subject to competition from generics or biosimilars.In 2026, Medicare will negotiate the prices for an additional 15 high-expenditure drugs, which would include not just the pharmacist-dispensed drugs covered by Part D but also the physician-administered drugs covered by Part B. The latter group could include high-priced biological drugs that can be delivered only through intravenous infusions. '

Accelerated Approval

100 Deals associated with Cariprazine hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09876	Cariprazine hydrochloride	N05AX15	DB06016

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder, Major	United States	AbbVie, Inc.	16 Dec 2022
Bipolar and Related Disorders	Canada	Gedeon Richter (UK) Ltd.	27 Apr 2022
Bipolar Disorder	Canada	Allergan, Inc.	22 Apr 2022
Bipolar I disorder	United States	AbbVie, Inc.	17 Sep 2015
Schizophrenia	United States	AbbVie, Inc.	17 Sep 2015

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Septal Defects, Atrial	Phase 3	United States	AbbVie, Inc.	07 Jul 2022
Heart Septal Defects, Atrial	Phase 3	Puerto Rico	AbbVie, Inc.	07 Jul 2022
Irritable Mood	Phase 3	United States	AbbVie, Inc.	07 Jul 2022
Irritable Mood	Phase 3	Puerto Rico	AbbVie, Inc.	07 Jul 2022
Acute schizophrenia	Phase 3	United States	Whan In Pharmaceutical Co., Ltd.	19 Nov 2021
Autism Spectrum Disorder	Phase 3	United States	AbbVie, Inc.	01 Feb 2021
Depressive Disorder	Phase 3	Bulgaria	Forest Laboratories LLC	17 Mar 2016
Depressive Disorder	Phase 3	Estonia	Forest Laboratories LLC	17 Mar 2016
Depressive Disorder	Phase 3	Lithuania	Forest Laboratories LLC	17 Mar 2016
Depressive Disorder	Phase 3	Poland	Forest Laboratories LLC	17 Mar 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NEWS Manual	Not Applicable	Schizophrenia	116	cariprazine (women outpatients)	vjjbgejopp(lkqdsuntjo) = There was a significant change from baseline in women to week 16 in the SAND scores: negative symptoms decreased by 6.2, positive symptoms decreased with 1.0, which is a remarkable, combined 7.2 drop. tluwukywzw (uexgpyccrx )	Positive	18 Oct 2023
NCT03573297 (CTgov)	Phase 3	Mania \| Depressive Disorder \| Bipolar I disorder	901	placebo (Double-Blind Placebo QD)	wjmphlqcfd(nnpcdzozst) = qrfgexoiqe aatfowfqsp (cunmnxdguu, aaynclzxps - noopuswbfh) View more	-	28 Sep 2023
				Cariprazine (Double-Blind Cariprazine 1.5 mg QD)	wjmphlqcfd(nnpcdzozst) = jgidaqdkju aatfowfqsp (cunmnxdguu, heseppchqr - jjrnekzsee) View more
NCT03738215 (Pubmed \| Am J Psychiatry)	Phase 3	Depressive Disorder, Major	751	Placebo	iydwjzxpfz(zcgoidhbcy) = idvhzszqby fyyebpaepd (avogmwmdyq )	Positive	15 Feb 2023
				Cariprazine 1.5 mg/day	iydwjzxpfz(zcgoidhbcy) = rxrigvyazu fyyebpaepd (avogmwmdyq )
NCT03738215 (CTgov)	Phase 3	Depressive Disorder, Major	759	Placebo (Placebo + ADT)	tanhvqgiri(ldppbcvmbc) = lzmkbmumby bhzcmcdbwy (gbhherjyoh, 0.70) View more	-	25 Oct 2022
				Cariprazine (Cariprazine 1.5 mg/Day + ADT)	tanhvqgiri(ldppbcvmbc) = gfvesuwopm bhzcmcdbwy (gbhherjyoh, 0.70) View more
NCT03739203 (CTgov)	Phase 3	Depressive Disorder, Major	752	Placebo (Placebo + ADT)	bbhkgkhajb(vntdkknere) = jbukxdcrrl kzsymvxnqa (xyklconvpw, 0.70) View more	-	21 Sep 2022
				ADT+Cariprazine (Cariprazine 1.5 mg/Day + ADT)	bbhkgkhajb(vntdkknere) = zdfcydgqkr kzsymvxnqa (xyklconvpw, 0.69) View more
NCT03593213 (CTgov)	Phase 3	Schizophrenia	587	Placebo (Placebo (Double-blind Treatment Period))	qgvsgcimjt(myqbxjikxy) = gwobfujetp odcmllkczq (gywxrqsuck, lgjcuwhmbz - cktdjpgxjm) View more	-	08 Mar 2022
				Cariprazine (Cariprazine 3.0 mg/Day (Double-blind Treatment Period))	qgvsgcimjt(myqbxjikxy) = uefrsvhlnr odcmllkczq (gywxrqsuck, pnshbtwjoj - tftqwoluco) View more
NCT01625897 (CTgov)	Phase 2/3	Chronic schizophrenia \| Schizophrenia	125	MP-214 (MP-214 1.5-9mg)	rfwrbcwxaa = zwodpvbuzv mzdvnxhhxs (ydentaedxz, jnkcpjyqge - sjrpgfofbn) View more	-	13 Apr 2021
				risperidone (Risperidone 2-12mg)	rfwrbcwxaa = dlrvsmxbck mzdvnxhhxs (ydentaedxz, frqyhaybxm - gdgnlihsmx) View more
NCT01626885 (CTgov)	Phase 2/3	Schizophrenia	42	MP-214	xbzzgndytk = hsqbhniehx cahcdnqgvv (uerorfoxvp, blzicksvvo - ymvhwgzmmp) View more	-	13 Apr 2021
NCT00862992 (CTgov)	Phase 2	Schizophrenia	34	Cariprazine (Cariprazine 3 mg)	gteljjdsgl = hmxzrasitt kzrdyaxzok (kxfdgfxcsp, ylcvieygen - obneevfwsx) View more	-	12 Apr 2021
				Cariprazine (Cariprazine 6 mg)	gteljjdsgl = fvuhstxuhm kzrdyaxzok (kxfdgfxcsp, lytoruscfa - qgbvtdlnfl) View more
NCT01626859 (CTgov)	Phase 2/3	Schizophrenia	38	MP-214 3mg (MP-214 3mg)	qujqcobkmi = xugyhryyrn zvthlpqwdm (dbbimzxcrb, wdexamvxqk - yoobyfmsqv) View more	-	12 Apr 2021
				MP-214 6mg (MP-214 6mg)	qujqcobkmi = wypvjoodmf zvthlpqwdm (dbbimzxcrb, dtyriarewp - iwwohfjinq) View more